Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

Apr 04 2017

• By Emily Hayes

T-cells attacking cancer_1200x675

Related Content

Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma

Jun 02 2014

Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

Jun 01 2015

Under Fire, Bristol Plans To Pick Up The IO Pieces

Jan 27 2017

Related Companies

Bristol Myers Squibb Company

Additional Topics

ImmunoOncology Clinical Trials Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window